Home » Stocks » FULC

Fulcrum Therapeutics, Inc. (FULC)

Stock Price: $13.87 USD -0.08 (-0.57%)
Updated Jan 21, 2021 12:16 PM EST - Market open
Market Cap 383.10M
Revenue (ttm) 4.60M
Net Income (ttm) -69.22M
Shares Out 27.26M
EPS (ttm) -14.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $13.87
Previous Close $13.95
Change ($) -0.08
Change (%) -0.57%
Day's Open 14.00
Day's Range 13.44 - 14.13
Day's Volume 88,562
52-Week Range 7.22 - 22.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with geneti...

GlobeNewsWire - 1 day ago

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with geneti...

GlobeNewsWire - 1 day ago

Owen Wallace to Transition to Scientific Advisory Board Owen Wallace to Transition to Scientific Advisory Board

GlobeNewsWire - 1 month ago

Event will review the company's novel approach to inducing fetal hemoglobin

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genet...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genet...

Seeking Alpha - 2 months ago

Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics (FULC).

Zacks Investment Research - 2 months ago

Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 2 months ago

Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058 Screening of healthy volunteers initiated in Phase 1 clinical trial of FTX-6058

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genet...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) --   Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with gen...

GlobeNewsWire - 3 months ago

- Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease

GuruFocus - 4 months ago

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) revealed late last week his firm upped its stake in Dave & Buster's Entertainment Inc.

Other stocks mentioned: PLAY
GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with g...

Seeking Alpha - 5 months ago

Fulcrum Therapeutics Inc. (FULC) CEO Robert Gould on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

– Conference call scheduled for 8:00 a.m. ET today –

GlobeNewsWire - 5 months ago

Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expression

Zacks Investment Research - 5 months ago

Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 5 months ago

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

Other stocks mentioned: ARCT, AVRO, ETNB, ICPT
Zacks Investment Research - 5 months ago

Fulcrum Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 6 months ago

Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression Collaboration w...

Investors Business Daily - 6 months ago

Fulcrum stock gapped up Wednesday after the Food and Drug Administration gave it the go-ahead to begin a coronavirus treatment study. The drug is also in testing for muscular dystrophy.

24/7 Wall Street - 6 months ago

The U.S. Food and Drug Administration (FDA) has notified Fulcrum Therapeutics Inc.

Zacks Investment Research - 6 months ago

Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 6 months ago

Fulcrum receives early notification from U.S. Food and Drug Administration (FDA) that study may proceed Fulcrum receives early notification from U.S. Food and Drug Administration (FDA) that st...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC) today announced the closing of a $68.5 million private placement pursuant to a securities pu...

GlobeNewsWire - 7 months ago

Investigational New Drug (IND) application submitted; Company preparing to initiate Phase 3 trial

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).

Seeking Alpha - 8 months ago

Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Conference call scheduled for 8:00 a.m. ET today Conference call scheduled for 8:00 a.m. ET today

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with g...

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with g...

GlobeNewsWire - 9 months ago

– Losmapimod achieves target engagement in muscle –

Seeking Alpha - 10 months ago

Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ge...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ge...

Zacks Investment Research - 1 year ago

Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.

Benzinga - 1 year ago

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

Other stocks mentioned: ALEC, AMGN, RARE, RDUS, SAGE, SRPT, VRTX
Seeking Alpha - 1 year ago

Fulcrum Therapeutics' (FULC) CEO Robert Gould on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumer...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...

GlobeNewsWire - 1 year ago

Strode brings experience leading regulatory affairs and quality assurance across multiple therapeutic areas, including rare diseases with high unmet need

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...

GlobeNewsWire - 1 year ago

– Completed initial public offering, raising $72.0 million in gross proceeds –

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with ge...

Benzinga - 1 year ago

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) made its public debut on Thursday morning, opening at $14.50 after being priced at $16 per share.

About FULC

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upre... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2019
CEO
Dr. Robert J. Gould
Employees
73
Stock Exchange
NASDAQ
Ticker Symbol
FULC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is 18.17, which is an increase of 31.00% from the latest price.

Price Target
$18.17
(31.00% upside)
Analyst Consensus: Buy